A Message From Our Program Leader, Allison Steele, D.O.
We lead clinical research, exploring innovative drug and device therapies for metabolic disorders. Our program offers both procedural and emerging non-surgical options, working closely with the other programs and divisions to improve outcomes and expand treatment choices for patients.
About Our Program
The Metabolic Disorders Program is dedicated to advancing innovative therapies for type 2 diabetes, with additional research in type 1 diabetes and associated comorbidities across adult and pediatric populations.
In collaboration with the surgical program, interventional gastroenterology, and the cardiovascular division, we offer both procedural and emerging non-surgical treatment options, including novel GLP-1–based therapies and device-driven interventions.
Our active clinical trials are designed to evaluate the safety and efficacy of these approaches, aiming to improve glycemic control, metabolic outcomes, and long-term health for individuals living with diabetes.
Metabolic Disorders Research Facts and Figures
About 1 in 3 adults have prediabetes, and over 80% are unaware of it. In 2020, 73.6% of adults were overweight and 40.3% were obese. Prediabetes significantly increases the risk of developing type 2 diabetes.
Diabetes is closely linked to cardiovascular disease, chronic kidney disease, and other metabolic conditions.
GLP-1 receptor agonists significantly lower hemoglobin A1c by over 1% and improve obesity/excess weight by up to 22% of total bodyweight.